Physician profile
Danielle Rivera
NPI 1992549844
$1,434.18
in general payments reported to CMS, 2019-2025
22 companies · $1,434 in 2025
The $1,434 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,434.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,434.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $172.12 | 2025 | Ozempic, Rybelsus |
| Medtronic, INC. | $157.19 | 2025 | Minimed 780g, Inceptiv |
| Bayer Healthcare Pharmaceuticals INC. | $127.74 | 2025 | |
| Sequel Med Tech, LLC | $120.85 | 2025 | Twiist |
| Tandem Diabetes Care, INC. | $117.33 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ascendis Pharma Endocrinology INC | $90.91 | 2025 | Yorvipath, Skytrofa |
| Corcept Therapeutics | $74.31 | 2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $68.60 | 2025 | Gvoke Hypopen |
| Amneal Pharmaceuticals LLC | $65.09 | 2025 | Unithroid |
| Neurocrine Biosciences, INC. | $61.67 | 2025 | |
| Rhythm Pharmaceuticals, INC. | $56.36 | 2025 | Imcivree |
| Astrazeneca Pharmaceuticals Lp | $56.12 | 2025 | Farxiga |
| Abbott Laboratories | $45.14 | 2025 | Freestyle Libre 3 |
| Amgen INC. | $43.23 | 2025 | Tepezza, Evenity |
| Lilly USA, LLC | $36.00 | 2025 | Zepbound |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $26.50 | 2025 | Rezdiffra |
| Insulet Corporation | $23.70 | 2025 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.45 | 2025 | Jardiance |
| Glaxosmithkline, LLC. | $18.46 | 2025 | Shingrix, Arexvy |
| Tolmar, INC. | $18.07 | 2025 | Fensolvi |
| Novartis Pharmaceuticals Corporation | $18.00 | 2025 | |
| Abbvie INC. | $16.34 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.